ImageVerifierCode 换一换
格式:PDF , 页数:4 ,大小:92.85KB ,
资源ID:189778      下载积分:10 积分
快捷下载
登录下载
邮箱/手机:
温馨提示:
快捷下载时,用户名和密码都是您填写的邮箱或者手机号,方便查询和重复下载(系统自动生成)。 如填写123,账号就是123,密码也是123。
特别说明:
请自助下载,系统不会自动发送文件的哦; 如果您已付费,想二次下载,请登录后访问:我的下载记录
支付方式: 支付宝扫码支付 微信扫码支付   
验证码:   换一换

加入VIP,免费下载
 

温馨提示:由于个人手机设置不同,如果发现不能下载,请复制以下地址【https://www.wnwk.com/docdown/189778.html】到电脑端继续下载(重复下载不扣费)。

已注册用户请登录:
账号:
密码:
验证码:   换一换
  忘记密码?
三方登录: QQ登录  

下载须知

1: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。
2: 试题试卷类文档,如果标题没有明确说明有答案则都视为没有答案,请知晓。
3: 文件的所有权益归上传用户所有。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 本站仅提供交流平台,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

版权提示 | 免责声明

本文(ASTM_F_2024_-_10_2016.pdf)为本站会员(益****师)主动上传,蜗牛文库仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知蜗牛文库(发送邮件至admin@wnwk.com或直接QQ联系客服),我们立即给予删除!

ASTM_F_2024_-_10_2016.pdf

1、Designation:F202410(Reapproved 2016)Standard Practice forX-ray Diffraction Determination of Phase Content of Plasma-Sprayed Hydroxyapatite Coatings1This standard is issued under the fixed designation F2024;the number immediately following the designation indicates the year oforiginal adoption or,in

2、the case of revision,the year of last revision.A number in parentheses indicates the year of last reapproval.Asuperscript epsilon()indicates an editorial change since the last revision or reapproval.1.Scope1.1 This practice is for the determination,by the ReferenceIntensity Ratio External Standard M

3、ethod,of the percent byweight of the crystalline phases,hydroxyapatite(HA),beta-(whitlockite)tricalcium phosphate(-TCP),and calcium oxide(CaO)in coatings deposited upon metallic substrates byplasma-spraying hydroxyapatite.1.2 A major component in plasma-sprayed HA coatingsother than HA is expected t

4、o be amorphous calcium phosphate(ACP).Crystalline components other than HA that may bepresent include alpha-and beta-(whitlockite)tricalciumphosphates,tetracalcium phosphate(TTCP),calcium oxide,and calcium pyrophosphates.Quantification of the minorcrystalline components has proven to be very unrelia

5、ble due toextreme overlap and confounding of X-ray diffraction peaks.Therefore,this practice addresses the quantification of onlyHA,-TCP,and CaO.1.3 This practice was developed for plasma-sprayed HAcoatings with HA contents of at least 50%of the total coating.It is recognized that the analysis of th

6、e crystalline componentsuses diffraction from regions of the pattern that also includes asmall contribution from the amorphous component.However,within the limits of applicability of this practice,the effect ofsuch interference is believed to be negligible.1.4 The coating analyzed shall be produced

7、and processedunder equivalent manufacturing conditions to that on thedevice of interest.1.5 This practice requires the use of monochromated copperK radiation and flat samples.1.6 The values stated in SI units are to be regarded asstandard.No other units of measurement are included in thisstandard.1.

8、7 This standard does not purport to address all of thesafety concerns,if any,associated with its use.It is theresponsibility of the user of this standard to establish appro-priate safety and health practices and determine the applica-bility of regulatory limitations prior to use.2.Terminology2.1 Def

9、initions:2.1.1 crystalline phases:Chemical and MineralNamesFormulaPDF Card No.2whitlockitebeta-tricalcium phosphate-Ca3(PO4)29-169calcium phosphatealpha-tricalcium phosphate-Ca3(PO4)29-348limecalcium oxideCaO37-1497hydroxyapatite(hydroxylapatite)Ca5(PO4)3OH9-4322.2 plasma-sprayed hydroxyapatite coat

10、inga coating,consisting of at least 50%hydroxyapatite by weight,preparedby plasma-spraying hydroxyapatite on a substrate.3.Significance and Use3.1 Calcium phosphate coatings have been shown in animaland clinical studies to be biocompatible and to enhance theearly attachment of bone to implant surfac

11、es(see Refs.1-5)33.2 It is believed that the form of calcium phosphateceramic and its purity with respect to secondary crystallinephases and amorphous material have an effect on its physical,mechanical,and biological properties.However,no definitivestudies of effects on biological properties have be

12、en completed.To achieve reproducible clinical results and to permit thedetermination of the effects of properties of the coating onbiological performance,it is essential that the properties ofboth clinical and experimental materials be well-characterizedand consistent.1This practice is under the jur

13、isdiction ofASTM Committee F04 on Medical andSurgical Materials and Devices and is the direct responsibility of SubcommitteeF04.13 on Ceramic Materials.Current edition approved Oct.1,2016.Published October 2016.Originallyapproved in 2000.Last previous edition approved in 2010 as F2024 10.DOI:10.1520

14、/F2024-10R16.2Joint Committee on Powder Diffraction Standards,Swarthmore,PA.3The boldface numbers in parentheses refer to the list of references at the end ofthis standard.Copyright ASTM International,100 Barr Harbor Drive,PO Box C700,West Conshohocken,PA 19428-2959.United States1 3.3 This practice

15、provides procedures for determination ofthe percentage by weight of the crystalline phases identified ashydroxyapatite,-TCP and CaO in plasma-sprayed hydroxy-apatite coatings.4.Quantitative Phase Analysis by the External StandardTechnique4.1 The external standard technique allows the determina-tion

16、of weight fractions of individual phases in a mixturecontaining an amorphous fraction by comparison of the inte-grated intensity of one or more peaks from the phase(s)ofinterest to the external standard under identical instrumentalconditions(6).The sample analyzed may be a solid such as aplasma-sprayed coating or may be a powder.The massabsorption coefficients of the sample and standard must beknown.4.2 The weight fraction of the analyte phase in the mixtureis given by Equation 11 of Ref(6),as f

copyright@ 2008-2023 wnwk.com网站版权所有

经营许可证编号:浙ICP备2024059924号-2